Protein disulfide isomerase family 6 promotes the imatinib-resistance of renal cell carcinoma by regulation of Wnt3a-Frizzled1 axis

References

• Min Z. Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel. Front Biosci Landm. 2019;24(8):1452–1461
   PubMed Web of Science ®Google Scholar
• Marumo K, Kanayama H, Miyao N, et al. Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol. 2007;14(6):479–482.
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524.
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Haber T, Breuksch I, et al. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget. 2017;8(33):55230–55245.
   PubMedGoogle Scholar
• Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480.
   PubMed Web of Science ®Google Scholar
• Vuky J, Isacson C, Fotoohi M, et al. Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma. Invest New Drugs. 2006;24(1):85–88.
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367.
   PubMed Web of Science ®Google Scholar
• Okumura M, Kadokura H, Inaba K. Structures and functions of protein disulfide isomerase family members involved in proteostasis in the endoplasmic reticulum. Free Radic Biol Med. 2015;83:314–322.
   PubMed Web of Science ®Google Scholar
• Bai Y, Liu X, Qi X, et al. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway. EBioMedicine. 2019;42:311–325.
   PubMed Web of Science ®Google Scholar
• Kim T-W, Ryu -H-H, Li S-Y, et al. PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells. J Neurosurg. 2016;126(6):1829–1838.
   PubMed Web of Science ®Google Scholar
• Mao L, Wu X, Gong Z, et al. PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma. World J Surg Oncol. 2021;19(1):88.
   PubMed Web of Science ®Google Scholar
• Cheng H-P, Liu Q, Li Y, et al. The inhibitory effect of PDIA6 downregulation on bladder cancer cell proliferation and invasion. Oncol Res. 2017;25(4):587–593.
   PubMed Web of Science ®Google Scholar
• Tufo G, Jones AWE, Wang Z, et al. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ. 2014;21(5):685–695.
   PubMed Web of Science ®Google Scholar
• Yan C, Song X, Wang S, et al. Knockdown of PDIA6 inhibits cell proliferation and enhances the chemosensitivity in gastric cancer cells. Cancer Manag Res. 2020;12:11051–11062.
   PubMed Web of Science ®Google Scholar
• Gao C, Peng F, Peng L. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma. 2014;61(6):680–689.
   PubMed Web of Science ®Google Scholar
• Yuan J-B, Gu L, Chen L, et al. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis. Molecular Therapy-Oncolytics. 2021;22:36–51.
   Web of Science ®Google Scholar
• Popp HD, Brendel S, Hofmann W-K, et al. Immunofluorescence Microscopy of γH2AX and 53BP1 for analyzing the formation and repair of DNA double-strand breaks. J Vis Exp. 2017;129.
   Web of Science ®Google Scholar
• Powell LE, Foster PA. Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy. Cancer Med. 2021;10(8):2812–2825.
   PubMed Web of Science ®Google Scholar
• Fonseca C, Soiffer R, Ho V, et al. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009;113(8):1681–1688.
   PubMed Web of Science ®Google Scholar
• Kullmann M, Kalayda GV, Hellwig M, et al. Assessing the contribution of the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin resistance. J Inorg Biochem. 2015;153:247–252.
   PubMed Web of Science ®Google Scholar
• Higa A, Taouji S, Lhomond S, et al. Endoplasmic reticulum stress-activated transcription factor ATF6α requires the disulfide isomerase PDIA5 to modulate chemoresistance. Mol Cell Biol. 2014;34(10):1839–1849.
   PubMed Web of Science ®Google Scholar
• Rosell R, Karachaliou N. Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy. EBioMedicine. 2019;42:20–21.
   PubMed Web of Science ®Google Scholar
• Synowiec E, Hoser G, Wojcik K, et al. Oxidative Stress, DNA damage and apoptosis in BCR-ABL1-positive cells sensitive and resistant to imatinib. Int J Mol Sci. 2015;16(8):18111–18128.
   PubMed Web of Science ®Google Scholar
• Dinis J, Silva V, Gromicho M, et al. DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells. Leuk Lymphoma. 2012;53(10):2004–2014.
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Hien A, Zhang X, et al. Disulfide bond requirements for active Wnt ligands. J Biol Chem. 2014;289(26):18122–18136.
   PubMed Web of Science ®Google Scholar
• Gao H, Sun B, Fu H, et al. PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/β-catenin signaling pathway. Oncotarget. 2016;7(33):53289–53298.
   PubMedGoogle Scholar
• Jiang H, Tang J-Y, Xue D, et al. Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling. Cancer Cell Int. 2021;21(1):41.
   PubMed Web of Science ®Google Scholar
• Peng Q, Wang L, Zhao D, et al. Overexpression of FZD1 is associated with a good prognosis and resistance of sunitinib in clear cell renal cell carcinoma. J Cancer. 2019;10(5):1237–1251.
   PubMed Web of Science ®Google Scholar
• Su H, Jin X, Zhang X, et al. FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R. J Transl Med. 2015;13(1):104.
   PubMed Web of Science ®Google Scholar